Expertise in
1
conditions

Dr. Matthew G. Davis

Family Medicine
Office
500 Helendale Rd Ste L20, 
Rochester, NY 
Expertise in
1
conditions
Office
500 Helendale Rd Ste L20, 
Rochester, NY 

Overview

Matthew Davis is a primary care provider, practicing in Family Medicine in Rochester, New York.

Dr. Davis is highly rated in 1 condition, according to our data. His clinical expertise encompasses Migraine, Headache, Parainfluenza, and Severe Acute Respiratory Syndrome (SARS).

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 35 clinical trials.

Specialties

Family Medicine

Licenses

Family Medicine in NY

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO

Locations

Office
500 Helendale Rd Ste L20, Rochester, NY 14609

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

28 Clinical Trials

Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
Enrollment Status: Terminated
Publish Date: September 02, 2026
Intervention Type: Drug
Study Drug: Lasmiditan
Study Phase: Phase 3
A Phase I, First-Time-in Human (FTiH), Open-label, Dose Escalation, Non-randomized Study to Assess Safety, Reactogenicity and Immune Response of a CoV-2 SAM (LNP) Vaccine When Administered Intramuscularly on a 0, 1 Month Schedule in Healthy Adults 18 to 50 Years of Age
A Phase I, First-Time-in Human (FTiH), Open-label, Dose Escalation, Non-randomized Study to Assess Safety, Reactogenicity and Immune Response of a CoV-2 SAM (LNP) Vaccine When Administered Intramuscularly on a 0, 1 Month Schedule in Healthy Adults 18 to 50 Years of Age
Enrollment Status: Completed
Publish Date: August 24, 2026
Intervention Type: Biological
Study Drug: CoV-2 Self-Amplifying mRNA Lipid Nanoparticle Vaccine
Study Phase: Phase 1
A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above
A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above
Enrollment Status: Active_not_recruiting
Publish Date: July 14, 2026
Intervention Type: Biological
Study Drug: RSVPreF3 OA investigational vaccine
Study Phase: Phase 3
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
Enrollment Status: Terminated
Publish Date: June 25, 2026
Intervention Type: Drug
Study Drug: Lasmiditan
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD-1 Study
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD-1 Study
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Biological
Study Drug: RSVPreF3
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine PXVX0317 in Healthy Adults and Adolescents
Enrollment Status: Completed
Publish Date: August 30, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase II Study of a Primary Dose of Investigational RSV Maternal Vaccine, Given Alone or With Boostrix, With a 2nd Dose Investigational RSV Maternal Vaccine
A Phase II Study of a Primary Dose of Investigational RSV Maternal Vaccine, Given Alone or With Boostrix, With a 2nd Dose Investigational RSV Maternal Vaccine
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Biological, Drug
Study Drugs: RSVPreF3, Boostrix-ex-US, Boostrix-US
Study Phase: Phase 2
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
View 9 Less Clinical Trials

3 Total Publications

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.
Journal: The Journal of infectious diseases
Published: May 27, 2022
Similar Doctors
Expertise in
10
conditions
Dr. Azfar Ahmed
Family Medicine
Expertise in
10
conditions
Dr. Azfar Ahmed
Family Medicine

Trillium Health Pharmacy

170 Science Pkwy, 
Rochester, NY 
 (5.0 miles away)
585-545-7200
Languages Spoken:
English
See accepted insurances

Azfar Ahmed is a primary care provider, practicing in Family Medicine in Rochester, New York. Dr. Ahmed is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Acute Cystitis, Cholesteryl Ester Storage Disease, Wolman Disease, Endoscopy, and Ureteroscopy.

Expertise in
94
conditions
Dr. Min J. Yang
Family Medicine
Expertise in
94
conditions
Dr. Min J. Yang
Family Medicine

Office

325 Essjay Rd, 
Buffalo, NY 
 (61.3 miles away)
716-656-4851
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Min Yang is a primary care provider, practicing in Family Medicine in Buffalo, New York. Dr. Yang is highly rated in 94 conditions, according to our data. Her clinical expertise encompasses Acute Arterial Occlusion of Kidney, Pancreatic Islet Cell Tumor, Sepsis, Stent Placement, and Nerve Decompression.

Expertise in
2
conditions
Dr. Bradley M. Turner
Family Medicine
Expertise in
2
conditions
Dr. Bradley M. Turner
Family Medicine

Ur Medicine Labs-Highland Hospital

1000 South Ave, 
Rochester, NY 
 (3.9 miles away)
585-341-6779
Languages Spoken:
English
See accepted insurances

Bradley Turner is a primary care provider, practicing in Family Medicine in Rochester, New York. Dr. Turner is highly rated in 2 conditions, according to our data. His clinical expertise encompasses HER2 Negative Breast Cancer, Breast Cancer, Primary Lateral Sclerosis, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease).

Frequently Asked Questions about Dr. Matthew G. Davis

How do I make an appointment with Dr. Matthew G. Davis?

You can book an appointment with Dr. Matthew G. Davis by calling their office at 585-288-0890. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Matthew G. Davis a top-rated expert for Migraine?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Matthew G. Davis is classified as an Advanced expert for Migraine, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Matthew G. Davis specialize in?

While Dr. Matthew G. Davis is a Family Medicine, they have specific expertise in Migraine, Headache, and Parainfluenza. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Family Medicine.

Does Dr. Matthew G. Davis participate in research or clinical trials?

Yes. Dr. Matthew G. Davis has published 3 articles and abstracts on conditions like Migraine. You can view a list of Dr. Matthew G. Davis's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Matthew G. Davis accept my insurance?

Dr. Matthew G. Davis accepts most major insurance plans, including Blue Cross Blue Shield and Cigna. We recommend calling the office directly at 585-288-0890 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Davis's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile